Health CareCompany Update
Actinogen Medical (ASX: ACW) Alzheimer’s Trial Misses Primary Endpoint
Actinogen Medical’s pivotal XanaMIA Alzheimer’s trial missed its primary endpoint across the overall population. The company will conserve cash and examine a stronger result in patients older than 75.
![[ASX: ACW] ACTINOGEN MEDICAL LIMITED an older clinical-trial participant seated across from a medical researcher during a cognitive assessment, framed at desk](/media/hero/5f03c56a-8eb5-4737-9862-f99b683dad2c/1795058492006-4a0eef46-1536w.webp)
Listen to article
0:00 / 3:01Actinogen Medical’s pivotal XanaMIA study has failed to demonstrate a statistically significant benefit for Alzheimer’s patients across the overall trial population, prompting the biotechnology company to suspend future phase 3 spending while it examines a more favourable result among older participants.
The placebo-controlled trial tested a daily 10 mg dose of oral drug candidate Xanamem, also known as emestedastat, over 36 weeks in 247 people with mild to moderate Alzheimer’s disease and elevated levels of the pTau181 blood biomarker.
On the primary endpoint, Xanamem delivered a mean 0.10-point benefit over placebo on the Clinical Dementia Rating Scale–Sum of Boxes at week 36. The result was not statistically significant, with a p-value of 0.65.
That outcome is the central result for shareholders, despite evidence of a potentially stronger effect in a prespecified subgroup of patients above the trial’s median age of 75.
Older subgroup offers a development path
Among those older participants, 40% of Xanamem recipients recorded no disease progression at the end of treatment, compared with 22% on placebo. This difference was statistically significant, with a p-value of 0.02.
Actinogen also reported 30% slower disease progression in the subgroup, equivalent to a 0.39-point benefit on the same clinical scale at week 36. However, that measure was not statistically significant, recording a p-value of 0.22.
The company said older patients represent more than 70% of people with Alzheimer’s disease. It has filed new patent protection covering Xanamem’s use in older, more advanced patients and intends to discuss the results with potential co-development partners.
Small trends favouring Xanamem were also observed in cognition and activities of daily living, but the announcement did not establish statistically significant benefits on those secondary measures.
The final trial result was weaker than the study’s January 2026 interim analysis. Data used by the independent monitoring committee had shown a statistically significant 0.58-point benefit at week 24 among 88 participants, but this was not sustained in the final analysis of 247 patients.
Extension data and cash conservation
Actinogen will continue the trial’s open-label extension after the first 29 participants to complete 24 weeks of active treatment showed no mean disease progression. As the extension has no placebo comparison and the current dataset is small, the next update will be important in assessing whether that pattern persists. Results from about 100 participants with at least 24 weeks of treatment are expected in the first quarter of calendar 2027.
Xanamem was reported as safe and well tolerated over 36 weeks, with no serious adverse events attributed to the drug. More than 500 people have now received it across eight clinical trials, although it remains investigational and is not approved by any regulator.
Actinogen has moved to conserve cash by focusing spending on the extension study, further analysis, intellectual property and partner discussions. It has suspended future phase 3 expenditure.
The company held $18.9 million in cash and no debt at the announcement date, alongside an accrued research and development tax incentive. Actinogen expects its commitments to fall substantially from early 2027 and says its funding runway extends into calendar 2028.
Latest ACTINOGEN MEDICAL LIMITED ASX Announcements
- 19 Nov 2026 · 9:40 amReinstatement
- 19 Nov 2026 · 8:32 amCompany Update
- 17 Nov 2026 · 10:33 amTrading Halt / Suspension
- 13 Nov 2026 · 9:25 amOther
- 13 Nov 2026 · 9:22 amTrading Halt / Suspension
- 12 Nov 2026 · 4:29 pmSecurities Administration
- 12 Nov 2026 · 4:28 pmBuybacks & Capital Management
- 9 Nov 2026 · 4:31 pmASX Query
![[ASX: LDX] LUMOS DIAGNOSTICS HOLDINGS LIMITED a clinician in an urgent care examination room preparing a fingerstick blood sample beside a compact](/media/hero/14fdc9c1-090a-4cb4-838b-6ccac9e764af/1794196573830-a831dc31-640w.webp)
![[ASX: OCC] ORTHOCELL LIMITED a close-up composition of sustainably sourced pearl shells beside a small sample of processed bone graft biomaterial in](/media/hero/1d78f211-86f4-4939-97eb-81bda5f14669/1793764030563-b679e509-640w.webp)
![[ASX: CC5] CLEVER CULTURE SYSTEMS LIMITED a laboratory scientist loading culture plates into an automated analysis instrument within a clean pharmaceutical quality-control](/media/hero/8a1c5622-2122-437c-ac99-192f57d45b44/1793152635605-44fac865-640w.webp)
![[ASX: TGN] TUNGSTEN MINING NL an elevated view of a drilling rig operating along a cleared ridge within the Watershed mineralised corridor,](/media/hero/f225b2a3-50e0-4e12-bb05-26693d654759/1794794742442-3a7f2742-640w.webp)
![[ASX: ARL] ARDEA RESOURCES LIMITED a laboratory bench with sealed vessels of representative process liquor, ion-exchange resin columns and mineral-processing equipment, framed](/media/hero/db2a051d-85fe-49e7-8ae3-baf6d545abb0/1794439152752-dcd5db9d-640w.webp)
![[ASX: WCE] WEST COAST SILVER LIMITED a wide view of a diamond drill rig operating in the arid West Pilbara landscape south](/media/hero/cfccd740-5f90-4e54-9313-fc4a9c958e74/1794354529622-c28eff18-640w.webp)